NCT07169279: An ongoing trial by QED Therapeutics, a BridgeBio company
This trial is ongoing. It must report results 6 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07169279 |
|---|---|
| Title | Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 19, 2025 |
| Completion date | March 31, 2032 |
| Required reporting date | March 31, 2033, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |